October 01, 2024 – Oslo, Norway
We are excited to announce the appointment of Anders Tuv to ClexBio’s Board of Directors.
Anders is an experienced investment and business development professional with in-depth knowledge of the inner workings of the healthcare & biotech industry. As the Managing Director of Radforsk Invest, a Nordic life science investment fund, he has an active role in establishing, building and scaling multiple innovative early-stage biotech companies in immuno-oncology, radiopharmaceuticals and precision medicine.
Notably, he has been Board Chair of Nykode Therapeutics and Zelluna Therapeutics, and a Co-founder and Board Director of ArtBio. Companies Anders co-founded have raised financing from top tier VCs in the US and Europe and have struck global pharma industry deals worth several billion dollars.
Anders’ unique experience covering C-level management, strategy and business development, research collaborations, licensing deals, M&As and IPOs will be invaluable to ClexBio in our next phase of scaling. ClexBio will benefit from Anders’ broad network and expertise in fundraising as we continue to partner with the best investors in the space.
Welcome on board, Anders!
About ClexBio
ClexBio is a pre-clinical stage regenerative medicine company with a breakthrough platform for scalable, high-throughput generation of therapeutic tissues. We represent the next generation of cell therapy, leveraging fully functional bioengineered tissues to elevate the restorative ability of cells and produce a new class of curative treatments for some of the world’s most challenging medical conditions.
For all the latest updates, visit clexbio.com or follow us on LinkedIn.
